Immunity against SARS-CoV-2 in immune-suppressed patients: increased risk of insufficient immunological memory or sufficient protection against re-infection? A Target to B! substudy
Recruiting
- Conditions
- hematologische en andere B-cel gemedieerde aandoeningen10003816immunityimmunosuppressive medicationSARS-CoV-2 infection10047438
- Registration Number
- NL-OMON55289
- Lead Sponsor
- Academisch Medisch Centrum
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 5350
Inclusion Criteria
fase 1: auto-immune disease, treatment with at least one immunosuppressive
medication, SARS-CoV-2 infection
fase 2/group 1:auto-immune disease
fase 2/group 2: healthy control
Exclusion Criteria
Known pregnancy during study entry. Concomitant treatment with
immunosuppressive medication (like chemotherapy) for cancer or
organ-transplantation (including stem-cell transplantation).
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>• Effects of systemic immunosuppressive medication on the serologic response at<br /><br>28-days after the second SARS-CoV-2 vaccination<br /><br>• Difference in SARS-CoV-2-specific B- and T-cell frequencies and functional<br /><br>phe-notype and determinants thereof</p><br>
- Secondary Outcome Measures
Name Time Method